| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2014.60.1591 |
| P8608 | Fatcat ID | release_nhcy6kdjtbf5xhf7aluowqi7xq |
| P3181 | OpenCitations bibliographic resource ID | 956127 |
| P932 | PMC publication ID | 4534527 |
| P698 | PubMed publication ID | 26169613 |
| P50 | author | Tom Curran | Q7815488 |
| Arzu Onar-Thomas | Q91519746 | ||
| Amar Gajjar | Q92888059 | ||
| Sue C. Kaste | Q112113580 | ||
| Michael D Prados | Q114338680 | ||
| Murali Chintagumpala | Q41599004 | ||
| Giles Robinson | Q55459192 | ||
| Maryam Fouladi | Q61303209 | ||
| Richard Gilbertson | Q64746860 | ||
| Annick Desjardins | Q73536038 | ||
| Sridharan Gururangan | Q73536128 | ||
| Clinton F Stewart | Q88219529 | ||
| P2093 | author name string | David W Ellison | |
| Gang Wu | |||
| Tong Lin | |||
| Stewart Goldman | |||
| Sariah J Allen | |||
| Michael Rusch | |||
| Roger J Packer | |||
| James M Boyett | |||
| Ibrahim Qaddoumi | |||
| Naoko Takebe | |||
| Brent A Orr | |||
| P2860 | cites work | Molecular subgroups of medulloblastoma: the current consensus | Q24615271 |
| Dissecting the genomic complexity underlying medulloblastoma | Q24621907 | ||
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. | Q27851485 | ||
| Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition | Q27852966 | ||
| Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 | ||
| Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway | Q28594509 | ||
| Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
| The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma | Q35100720 | ||
| Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome | Q35184597 | ||
| Novel mutations target distinct subgroups of medulloblastoma. | Q36143877 | ||
| Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups | Q36460209 | ||
| Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables | Q36476670 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma | Q36929844 | ||
| Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study | Q37246499 | ||
| Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study | Q37375947 | ||
| Cytogenetic prognostication within medulloblastoma subgroups | Q37627692 | ||
| Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists | Q37902802 | ||
| Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance | Q39625099 | ||
| Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 | ||
| Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Q42282551 | ||
| PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition | Q42447112 | ||
| A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors | Q42454105 | ||
| Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations | Q43826621 | ||
| Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation | Q44485080 | ||
| Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure | Q46278000 | ||
| Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma | Q48477520 | ||
| Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. | Q52087418 | ||
| Loss of suppressor-of-fused function promotes tumorigenesis. | Q53334228 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| medulloblastoma | Q1333608 | ||
| P304 | page(s) | 2646-54 | |
| P577 | publication date | 2015-08-20 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. | |
| P478 | volume | 33 |
| Q93379325 | A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma |
| Q33665382 | A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience |
| Q90633426 | A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth |
| Q33577624 | A unified model of the hierarchical and stochastic theories of gastric cancer |
| Q48011531 | Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology |
| Q48116800 | Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. |
| Q92288318 | Applied Precision Cancer Medicine in Neuro-Oncology |
| Q39218100 | Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications |
| Q89944714 | CITK Loss Inhibits Growth of Group 3 and Group 4 Medulloblastoma Cells and Sensitizes Them to DNA-Damaging Agents |
| Q27612411 | CIViC database |
| Q88467059 | Case-based review: pediatric medulloblastoma |
| Q91641073 | Chidamide Inhibits Glioma Cells by Increasing Oxidative Stress via the miRNA-338-5p Regulation of Hedgehog Signaling |
| Q47282131 | Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. |
| Q92140233 | Childhood brain tumors: current management, biological insights, and future directions |
| Q37327524 | Cisplatin induces stemness in ovarian cancer |
| Q59129106 | Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome |
| Q51542148 | Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas. |
| Q41573477 | Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib |
| Q40191528 | Conditional loss of hepatocellular Hedgehog signaling in female mice leads to the persistence of hepatic steroidogenesis, androgenization and infertility |
| Q39441380 | Developing Cures: Targeting Ontogenesis in Cancer. |
| Q37171459 | Development of mediastinal lymphoma after radiotherapy for concurrent medulloblastoma and PNET in a patient with Gorlin syndrome |
| Q38728565 | Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog |
| Q57492122 | Different Response of Mutant and Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors |
| Q91665138 | EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma |
| Q64923739 | Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics. |
| Q38908981 | Emerging from their burrow: Hedgehog pathway inhibitors for cancer |
| Q92781644 | Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis |
| Q38837279 | Extracellular Regulation of the Mitotic Spindle and Fate Determinants Driving Asymmetric Cell Division |
| Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
| Q47106440 | Genipin suppresses colorectal cancer cells by inhibiting the Sonic Hedgehog pathway |
| Q58804574 | Genomics of adult and pediatric solid tumors |
| Q49548506 | Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis. |
| Q36612342 | Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations |
| Q38935571 | Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy |
| Q59792326 | Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells |
| Q39175185 | Hedgehog Signaling: From Basic Biology to Cancer Therapy |
| Q52431551 | Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. |
| Q55022167 | Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. |
| Q48115523 | Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors. |
| Q38675876 | Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma |
| Q64279216 | Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma |
| Q33677392 | Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center |
| Q42378333 | Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. |
| Q48530699 | Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. |
| Q34550706 | Loss of Pin1 Suppresses Hedgehog-Driven Medulloblastoma Tumorigenesis |
| Q91596369 | Medulloblastoma |
| Q55369639 | Medulloblastoma in a toddler with Gorlin syndrome. |
| Q42562593 | Medulloblastoma in adults: they're not just big kids |
| Q47133403 | Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. |
| Q54954567 | Medulloblastoma in the Molecular Era. |
| Q39225738 | Medulloblastoma: Molecular Classification-Based Personal Therapeutics |
| Q38791824 | Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm |
| Q39446793 | Medulloblastoma: experimental models and reality |
| Q64079587 | Medulloblastoma: optimizing care with a multidisciplinary approach |
| Q91826570 | Medulloblastomics revisited: biological and clinical insights from thousands of patients |
| Q37573700 | Molecular Classification of Medulloblastoma |
| Q90270316 | Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
| Q92865416 | Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches |
| Q50094787 | New Opportunities and Challenges to Defeat Cancer Stem Cells |
| Q31115540 | Non-invasive metabolic imaging of brain tumours in the era of precision medicine |
| Q38374250 | Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. |
| Q47944360 | Obstacles to Brain Tumor Therapy: Key ABC Transporters |
| Q50060950 | Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon |
| Q93162823 | Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma |
| Q92293472 | Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis |
| Q52091726 | Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. |
| Q64244529 | Polyamine Metabolism as a Therapeutic Target inHedgehog-Driven Basal Cell Carcinomaand Medulloblastoma |
| Q66680444 | Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors |
| Q64275194 | Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas |
| Q58565636 | Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial |
| Q57158811 | Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups |
| Q38676891 | Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations |
| Q91614261 | Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer |
| Q55403358 | Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. |
| Q57962903 | Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer |
| Q51230315 | Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4. |
| Q88993176 | Rethinking medulloblastoma from a targeted therapeutics perspective |
| Q36901551 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus |
| Q38768033 | SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development. |
| Q37690128 | Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. |
| Q49396658 | Sophoridine suppresses cell growth in human medulloblastoma through FoxM1, NF-κB and AP-1. |
| Q50043839 | Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. |
| Q91518791 | Stem cell fate in cancer growth, progression and therapy resistance |
| Q89667670 | Targeting cancer stem cell pathways for cancer therapy |
| Q38802190 | Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors |
| Q89185752 | Targeting mTOR as a Therapeutic Approach in Medulloblastoma |
| Q91620717 | Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update |
| Q36978748 | The Fallacy of Univariate Solutions to Complex Systems Problems |
| Q92830541 | The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers |
| Q39438064 | The evolution of medulloblastoma therapy to personalized medicine |
| Q26740373 | The hedgehog pathway in triple-negative breast cancer |
| Q91728273 | Therapeutic implications of germline genetic findings in cancer |
| Q51243084 | Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. |
| Q99408638 | Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma |
| Q47986450 | mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. |
| Q92163648 | scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy |
Search more.